This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
Kidney Cancer
RadiCal
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
FORT
NRG-GU 0101
Oral EPI-7386
RTIRE
SHORTER
SPLASH
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Translational Prostate Cancer
Andrea Miyahira, Ph.D
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
EnDOUROLOGY
Sumanta (Monty) Kumar Pal, MD||Jaime Landman, MD
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Health Policy
Ruchika Talwar, MD
WOMEN IN SCIENCE
Andrea Miyahira, Ph.D
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Suprapubic Catheter
Diane K. Newman, DNP FAAN BCB-PMD
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Pelvic
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2023
SNMMI 2023
ProsTIC/PCF Global Webinar 2023
ASCO 2023
AUA 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
SUO 2022
SUO 2022
Prostate Cancer
Bladder Cancer
Upper Tract Urothelial Carcinoma
SUO 2022 Bladder Cancer
Viewing 1-14 of 14 articles
SUO 2022: Intermediate Risk Non-Muscle Invasive Bladder Cancer: “New” Definitions
SUO 2022: Intermediate Risk: New Trials and Horizons
SUO 2022: Looking Towards the Future: Non-Muscle Invasive Bladder Cancer Trials Reading Out in 24 Months
SUO 2022: Utility of Cxbladder Monitor in Surveillance
SUO 2022: BCG Naïve - FDA: 1 Year from Symposia
SUO 2022: “Remote” Monitoring in Urologic Cancer: The Case for Home Based Testing in Bladder Cancer
SUO 2022: Revisiting Neoadjuvant Therapy Before Prostatectomy
SUO 2022: Addressing Mental Illness and Suicidality in Men With Prostate Cancer
SUO 2022: A Phase 1 Dose-escalation Study of UGN-301 (Zalifrelimab) as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer
SUO 2022: A Phase 3 Single-Arm Study of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
SUO 2022: Real Life Impact of Cxbladder Tests on Diagnosis and Surveillance of Bladder Cancer
SUO 2022: Neoadjuvant Chemotherapy and Bladder Sparing Surgery for Muscle Invasive Bladder Cancer: An Old-New De-Escalation Strategy
SUO 2022: The Impact of Blue Light Cystoscopy on Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients Treated in a Real-World Setting
SUO 2022: Real-World Pembrolizumab Utilization Patterns for High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Claims-Based Analysis
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free